Coleus forskohlii Briq. is the name used for Gandira root in the Ayurvedic Pharmacopoeia of India (API). Current Kew taxonomy treats that name as a synonym of Coleus barbatus var. barbatus, while Plectranthus barbatus is a synonym of Coleus barbatus. The root contains diterpenes including forskolin, an important experimental activator of adenylyl cyclase and cyclic AMP (cAMP). That mechanism is established, but claims that oral Coleus products reliably treat obesity, hypothyroidism, glaucoma, or heart failure exceed the clinical evidence.

Botanical Profile and Ayurvedic Context

The API identifies Gandira as the dried mature root of Coleus forskohlii Briq., synonym C. barbatus Benth., family Lamiaceae. It describes a perennial branched aromatic herb found in the subtropical western Himalayas, Nilgiri hills, Gujarat, and Bihar and cultivated in Maharashtra. Its official Sanskrit synonym is Gandira (Sthalaja). The API calls the identity controversial and provisionally accepts this species as the terrestrial, or Sthalaja, Gandira, so older vernacular names should not be treated as botanically conclusive.

The root is described as light brown, wrinkled, tapering, pleasantly aromatic, and slightly bitter and pungent. Listed constituents include diterpenes, coleonol, coleosol, deoxy-coleonol, forskohlin, naphthopyrone, and coleoforsine. This constituent list does not mean that every raw root or commercial extract has an identical chemical profile.

Ayurvedic Properties According to the API

The API records rasa as katu, tikta, and kashaya; guna as ruksha, sara, and tikshna; virya as ushna; and vipaka as katu. Listed karma are kaphahara, vatahara, tridoshahara, vranashodhana, and vidahi. These are traditional Ayurvedic descriptors, not modern receptor-level mechanisms.

Therapeutic uses listed in the monograph are shula, shotha, arsha, gulma, kasa, krimi, kushtha, udara, dushta vrana, hutavisha, pliharoga, mandagni, mutrabandha, and malabandha. The named formulation is Krimighna Kashaya Churna. These entries document recognized Ayurvedic use; they do not by themselves prove efficacy for a biomedical diagnosis.

Mechanism of Action: Adenylyl Cyclase and cAMP

Classic experiments showed that forskolin directly activates adenylyl cyclase in isolated membranes and intact cells (PMID: 6267587). The enzyme converts ATP to cAMP, which can signal through protein kinase A, exchange proteins directly activated by cAMP, and other effectors. Responses vary by cyclase isoform, tissue, concentration, and experimental conditions, so the claim that forskolin uniformly raises cAMP in every cell is too broad.

  • Adipose tissue: forskolin is used experimentally to raise cAMP and stimulate lipolytic signaling; this does not itself prove sustained human fat loss.
  • Thyroid tissue: forskolin can reproduce cAMP-dependent aspects of thyrotropin signaling, iodine metabolism, and secretion in experimental preparations, not clinical hypothyroidism treatment.
  • Cardiovascular tissue: cAMP can alter contractility and vascular tone, explaining historical intravenous studies but not validating oral root products.
  • Eye: topical forskolin has been studied for lowering intraocular pressure by reducing aqueous-humor inflow; oral supplements are a different intervention.

Forskolin is therefore a useful research tool, but a plausible pathway is not proof of therapeutic benefit. Route, dose, formulation, target tissue, duration, clinical endpoints, and adverse effects must be tested directly.

Clinical Evidence for Body Composition

A randomized 12-week trial enrolled 30 overweight or obese men: 15 received 250 mg of a 10% forskolin extract twice daily and 15 received placebo. The study reported lower body-fat percentage and fat mass, increased bone mass, and higher serum free testosterone relative to placebo. Lean body mass showed only a trend (p=0.097), not a significant increase. The trial was small and has not been confirmed by a large independent replication (PMID: 16129715).

A separate randomized trial in mildly overweight women used the same nominal regimen for 12 weeks, with 19 participants in the reported analysis. It found no significant benefit for body weight, fat mass, fat-free mass, lean mass, or body-fat percentage. No clinically significant changes in heart rate, blood pressure, thyroid hormones, routine laboratory measures, or reported side effects were detected, but this small short trial cannot establish long-term safety (PMID: 18500958).

A later study combined 250 mg of extract twice daily with a hypocaloric diet for 12 weeks; 30 adults completed it. Some insulin-related measures improved in the extract group, while anthropometric changes occurred in both groups. The small sample and simultaneous calorie restriction prevent this trial from proving that forskolin alone causes meaningful weight loss (PMID: 26593941).

Thyroid, Eye, and Cardiovascular Research

Forskolin stimulated adenylyl cyclase, cAMP accumulation, iodine metabolism, and thyroid-hormone secretion in experimental thyroid preparations (PMIDs: 6298030 and 6327383). These studies clarify signaling but do not demonstrate that an oral supplement treats subclinical or overt hypothyroidism. No adequately powered randomized clinical trial establishing such a benefit was identified.

Topical ocular research found reduced intraocular pressure through lower aqueous inflow (PMID: 6538189). This does not support oral or non-sterile self-treatment; glaucoma requires an ophthalmologist. Small historical studies of intravenous forskolin in congestive or dilated cardiomyopathy reported acute reductions in preload, afterload, and pulmonary pressures or improved left-ventricular function (PMIDs: 1696672 and 3593453). They do not establish oral Gandira or forskolin supplements as heart-failure therapy.

Evidence Overview

The verified studies below separate experimental pharmacology from limited clinical outcomes and show why route and formulation must always be stated.

Study PMID Population/model Exposure Interpretation
Seamon et al. 6267587 Membranes and intact cells Experimental forskolin Adenylyl cyclase activation and higher cAMP
Godard et al. 16129715 30 overweight or obese men 250 mg of 10% extract twice daily, 12 weeks Lower fat percentage and mass; lean-mass change not significant
Henderson et al. 18500958 19 women analyzed Same nominal regimen, 12 weeks No significant body-composition benefit
Loftus et al. 26593941 30 adults completing trial Extract plus hypocaloric diet, 12 weeks Some insulin-related improvement; isolated weight effect unproven
Baumann et al. 1696672 Congestive cardiomyopathy Acute intravenous forskolin Monitored hemodynamic effects, not evidence for oral supplements

cAMP Signaling Pathway Infographic

This mechanism map summarizes experimental relationships; it is not a list of proven clinical indications.

FORSKOLIN AND cAMP SIGNALING
Forskolin
experimental activator
→
Adenylyl cyclase
ATP → cAMP
→
cAMP
PKA and EPAC signaling

Adipose
experimental lipolytic signaling
Thyroid
ex vivo iodine and secretion responses
Cardiovascular
acute inotropic and vascular effects
Eye
topical reduction of aqueous inflow

Safety Considerations

Small 12-week oral trials did not reveal major safety signals, but they cannot establish long-term safety or safety in pregnancy, breastfeeding, children, surgery, or serious heart, blood-pressure, bleeding, eye, liver, kidney, or thyroid disorders. Commercial products may also differ from the trial extracts.

Forskolin has cardiovascular activity, and laboratory research found inhibition of human platelet aggregation (PMID: 6818975). People using antihypertensive, antiplatelet, anticoagulant, heart-failure, rhythm, thyroid, or glaucoma medicines should not add Coleus without professional review. Seek care for fainting, marked dizziness, palpitations, unusual bleeding, chest pain, breathing difficulty, or acute visual symptoms. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before use, especially with a diagnosed condition or prescription medicine.

Dosage and Product Quality

The API gives an adult oral dose of 3-5 g for dried Gandira root. This is not interchangeable with a concentrated extract. The regimen of 250 mg of 10% extract twice daily, nominally 50 mg forskolin per day, is a dose studied in small body-composition trials, not a universally established therapeutic dose.

API standards include foreign matter not more than 2%, total ash not more than 9%, acid-insoluble ash not more than 1.5%, alcohol-soluble extractive not less than 16%, water-soluble extractive not less than 23%, essential oil not less than 0.1%, and coleonol not less than 0.15%. A finished extract claiming a forskolin percentage needs a suitable validated assay and batch-specific quality control; the API root monograph does not certify every commercial extract.

Conclusion

Gandira has an authentic API monograph defining its identity, Ayurvedic properties, uses, dose, and quality standards. Forskolin has a verified role as an experimental activator of adenylyl cyclase and cAMP signaling. Clinical evidence is narrower: two small body-composition trials were inconsistent, thyroid evidence is preclinical, ocular findings concern topical use, and cardiovascular findings largely concern intravenous administration. Coleus should therefore not be promoted as a proven treatment for obesity, hypothyroidism, glaucoma, or heart failure. Safe use requires correct identification, a suitable preparation, realistic claims, and qualified supervision.

References

  1. Ayurvedic Pharmacopoeia of India
  2. Powo (powo.science.kew.org)
  3. Powo (powo.science.kew.org)
  4. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells (1981), PubMed
  5. Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes (1982), PubMed
  6. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men (2005), PubMed
  7. Link (link.springer.com)
  8. Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial (2015), PubMed
  9. Stimulation by forskolin of the thyroid adenylate cyclase, cyclic AMP accumulation and iodine metabolism (1983), PubMed
  10. Forskolin stimulation of thyroid secretion of T4 and T3 (1984), PubMed
  11. Forskolin lowers intraocular pressure by reducing aqueous inflow (1984), PubMed
  12. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy–a comparative study with dobutamine and sodium nitroprusside (1990), PubMed
  13. Effects of forskolin on left ventricular function in dilated cardiomyopathy (1987), PubMed
  14. Forskolin (a powerful inhibitor of human platelet aggregation) (1982), PubMed
  15. Uptake of bilirubin by the liver (1983), PubMed
  16. Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase (1986), PubMed
  17. The fungal hydrophobin RolA recruits polyesterase and laterally moves on hydrophobic surfaces (2005), PubMed
  18. Radiographic diagnosis of dental caries (2001), PubMed
  19. Pubchem (pubchem.ncbi.nlm.nih.gov)